Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Novel therapeutics in essential thrombocythemia

Lucia Masarova • 10 Dec 2022
ASH 2022
Essential Thrombocythemia Myeloproliferative Neoplasms Rare Diseases Interferon

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest advances in therapeutics for essential thrombocythemia (ET), including LSD1 inhibitors and interferon therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lucia Masarova

1:19
What's on the horizon for the treatment of MPNs?
Lucia Masarova • 9 Dec 2023
2:13
Splicing mutations in post-ET/post-PV myelofibrosis
Lucia Masarova • 9 Dec 2023
3:17
Estimating transfusion-related medical costs & time burden in patients with MF in SIMPLIFY-1
Lucia Masarova • 9 Dec 2023
3:18
Cladribine-based chemotherapy for patients with secondary AML arising after MPNs
Lucia Masarova • 9 Dec 2023

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals